Lyra Therapeutics (LYRA) Revenue (2021 - 2025)
Quarterly Revenue fell 96.65% to $7000.0 in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $398000.0 through Dec 2025, down 74.05% year-over-year, with the annual reading at $398000.0 for FY2025, 74.05% down from the prior year.
Lyra Therapeutics' Revenue history spans 5 years, with the latest figure at $7000.0 for Q4 2025.
- Revenue came in at $7000.0 for Q4 2025, down from $25000.0 in the prior quarter.
- In the past five years, Revenue ranged from a high of $598000.0 in Q2 2024 to a low of $7000.0 in Q4 2025.
- The 5-year median for Revenue is $240000.0 (2021), against an average of $285444.4.
- Year-over-year, Revenue surged 2464.29% in 2022 and then plummeted 96.65% in 2025.
- Lyra Therapeutics' Revenue stood at $271000.0 in 2021, then tumbled by 95.94% to $11000.0 in 2022, then surged by 1227.27% to $146000.0 in 2023, then surged by 43.15% to $209000.0 in 2024, then tumbled by 96.65% to $7000.0 in 2025.
- Per Business Quant, the three most recent readings for LYRA's Revenue are $7000.0 (Q4 2025), $25000.0 (Q3 2025), and $183000.0 (Q2 2025).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Revenue (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 1,384,976.65 Bn | 1,384,976.64 Bn | - | - |
| 2 | Alterity Therapeutics | 777,208.84 Bn | 777,208.81 Bn | - | - |
| 3 | Legend Biotech | 2,801.00 Bn | 2,800.10 Bn | 242.10 Mn | 306.30 Mn |
| 4 | Nanobiotix | 2,226.01 Bn | 2,225.95 Bn | - | - |
| 5 | Akari Therapeutics | 605.66 Bn | 605.66 Bn | - | - |
| 6 | Vertex Pharmaceuticals | 110.17 Bn | 102.92 Bn | 2.59 Bn | 2.99 Bn |
| 7 | Regeneron Pharmaceuticals | 66.86 Bn | 58.11 Bn | 3.31 Bn | 3.61 Bn |
| 8 | Evaxion A | 65.12 Bn | 65.10 Bn | - | - |
| 9 | Alnylam Pharmaceuticals | 39.94 Bn | 36.94 Bn | 959.66 Mn | 1.17 Bn |
| 10 | Lyra Therapeutics | - | - | - | 7,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 7,000.00 |
| Sep 30, 2025 | 25,000.00 |
| Jun 30, 2025 | 183,000.00 |
| Mar 31, 2025 | 183,000.00 |
| Dec 31, 2024 | 209,000.00 |
| Sep 30, 2024 | 195,000.00 |
| Jun 30, 2024 | 598,000.00 |
| Mar 31, 2024 | 532,000.00 |
| Dec 31, 2023 | 146,000.00 |
| Sep 30, 2023 | 544,000.00 |
| Jun 30, 2023 | 458,000.00 |
| Mar 31, 2023 | 410,000.00 |
| Dec 31, 2022 | 11,000.00 |
| Sep 30, 2022 | 359,000.00 |
| Jun 30, 2022 | 525,000.00 |
| Mar 31, 2022 | 468,000.00 |
| Dec 31, 2021 | 271,000.00 |
| Sep 30, 2021 | 14,000.00 |